Fujisawa Toshio, Joshi Bharat H, Takahashi Sho, Takasaki Yusuke, Suzuki Akinori, Ito Koichi, Ochiai Kazushige, Tomishima Ko, Ishii Shigeto, Puri Raj K, Isayama Hiroyuki
Department of Gastroenterology, Graduate School of Medicine, Juntendo University, Tokyo 113-8421, Japan.
Tumor Vaccines and Biotechnology Branch, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD 20993, USA.
Diagnostics (Basel). 2021 Jun 23;11(7):1140. doi: 10.3390/diagnostics11071140.
IL-13Rα2 is a high-affinity binding protein for its ligand IL-13 and a cancer-testis antigen as it is expressed in the testis. IL-13Rα2 is highly expressed in various cancers, including pancreatic cancer, and consists of three domains: extracellular, transmembrane, and cytoplasmic. The extracellular domain binds to the ligand to form a biologically active complex, which initiates signaling through AP-1 and other pathways. IL-13Rα2 is also expressed in diseased cells such as fibroblasts that are involved in various inflammatory diseases, including cancer. We have reported that IL-13Rα2 is a prognostic biomarker for malignant glioma, adrenocortical cancer, and pancreatic cancer. In pancreatic cancer, a small sample of tissue could be examined for the expression of IL-13Rα2 by using the endoscopic ultrasound-fine needle aspiration technique (EUS-FNA). In addition, a peptide-based targeted approach using Pep-1L peptide could be used to study the biodistribution and whole-body cancer imaging for the screening of pancreatic cancer in suspected subjects.
IL-13Rα2是其配体IL-13的高亲和力结合蛋白，也是一种癌-睾丸抗原，因为它在睾丸中表达。IL-13Rα2在包括胰腺癌在内的多种癌症中高表达，由三个结构域组成：细胞外结构域、跨膜结构域和细胞质结构域。细胞外结构域与配体结合形成生物活性复合物，该复合物通过AP-1和其他途径启动信号传导。IL-13Rα2也在诸如参与包括癌症在内的各种炎症性疾病的成纤维细胞等病变细胞中表达。我们已经报道IL-13Rα2是恶性胶质瘤、肾上腺皮质癌和胰腺癌的预后生物标志物。在胰腺癌中，可通过使用内镜超声细针穿刺技术（EUS-FNA）检查少量组织样本中IL-13Rα2的表达。此外，使用Pep-1L肽的基于肽的靶向方法可用于研究生物分布和全身癌症成像，以筛查疑似受试者中的胰腺癌。
